Study of the selectivity of insulin-like growth factor-1 receptor (IGF1R) inhibitors

Open Enzyme Inhibition Journal

Volumn 3, Issue 1, 2010, Pages 27-37

  Chène, Patrick ^a   Hau, Jean Christophe ^a   Blechschmidt, Anke ^a   Fontana, Patricia ^a   Bohn, Jacqueline ^a   Zimmermann, Catherine ^a   De Pover, Alain ^a   Erdmann, Dirk ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Insulin like growth factor 1 receptor; Kinase inhibitor; Protein kinase; Surface Plasmon Resonance

Indexed keywords

EID: 79954505731     PISSN: None     EISSN: 18749402     Source Type: Journal    
DOI: 10.2174/1874940201003010027     Document Type: Article

References (33)

1. [1] De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002; 1: 769-83.
2. [2] Adams TE , Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-93.
3. [3] Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
4. [4] Hartog H, Wesseling J, Boezen HM, Graaf WTA. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007; 43: 1895-904.
5. [5] Yuen JSP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment of cancer. Expert Opin Ther Targets 2008; 12: 589-603.
6. [6] Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathways as a therapeutic target in cancer. Oncologist 2008; 13: 16-24.
7. [7] Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat Clin Prat Oncol 2007; 4: 591-602.
8. [8] Paz K, Hadari YR. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Through Screen 2008; 11: 62-9.
9. [9] Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-1 receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575-88.
10. [10] Li R, Pourpak A, Morris SW. Inhibition of the Insulin-like Growth Factor Receptor-1 5IGF1R) tyrosine kinase as a novel therapy approach. J Med Chem 2009; 52: 4981-5004.
11. [11] Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997; 16: 5573-81.
12. [12] Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-1R kinase. Cancer Cell 2004; 5: 231-9.
13. [13] Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-1 receptor kinase inhibitor blocks insulin-like growth factor-1 receptor signaling in vitro and inhibits insulin-like growth factor-1 receptor-dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-67.
14. [14] Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 2000; 39: 15705-12.
15. [15] Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-1 receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007; 6: 1357-67.
16. [16] Erdmann D, Zimmermann C, Fontana P, Hau JC, De Pover A, Chène P. Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinase by triple infection in baculovirus expression system. J Biomol Tech 2010; 21(1): 9-17.
17. [17] Erdmann D, Allard B, Bohn J, et al. Kinetic study of human full-length wild-type JAK2 and V617F mutant proteins. Open Enzyme Inh J 2009; 1: 80-84.
18. [18] Morton TA, Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance. Meth Enzymol 1998; 295: 268-94.
19. [19] Önell A, Andersson K. Kinetic determinations of molecular interactions using Biacore - minimum data requirements for efficient experimental design. J Mol Recog 2005; 18: 307-17.
20. [20] Baer K, Al-Hasani H, Parvaresch S, et al. Dimerization-induced activation of soluble insulin/IGF-1 receptor tyrosine kinases: an alternative mechanism of activation. Biochemistry 2001; 2001: 14268-78.
21. [21] Ablooglu A, Kohanski RA. Activation of the insulin receptor's kinase domain changes the rate-determining step of substrate phosphorylation. Biochemistry 2001; 40: 504-13.
22. [22] Walker DH, Kuppuswamy D, Visvanathan A, Pike LJ. Substrate specificity and kinetic mechanism of human placental insulin receptor/kinase. Biochemistry 1987; 26: 1428-33.
23. [23] Segel IH. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems, New York, John Wiley & Sons, Inc., 1975.
24. [24] Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006; 11: 607-15.
25. [25] Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001; 8: 1058-63.
26. [26] Gruppuso PA, Boylan JM, Levine BA, Ellis L. Insulin receptor tyrosine kinase domain auto-dephosphorylation. Biochim Biophys Res Comm 1992; 189: 1457-63.
27. [27] Karlsson R, katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using affinity biosensors. Anal Biochem 2006; 349: 136-47.
28. [28] Li W, Favelyukis S, Yang J, et al. Inhibition of insulin-like growth factor I receptor autophosphorylation by 6-5 ring-fused compounds. Biochem Pharmacol 2004; 68: 145-54.
29. [29] Wu J, Li W, Craddock BP, Foreman KW, Mulvihill MJ, et al. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J 2008; 27: 1985-94.
30. [30] Tummino PJ, Copeland RA. Residence time of receptor#ligand complexes and its effect on biological function. Biochemistry 2008; 47: 5481-92.
31. [31] Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372: 746-54.
32. [32] Munshi S, Kornienko M, Hall DL, et al. Crystal structure of the apo, unactivated Insulin-like Growth factor-1 receptor kinase. J Biol Chem 2002; 277: 38797-802.
33. [33] Frankel M, Bishop S M, Ablooglu A J, Han Y P, Kohanski R A. Conformational changes in the activation loop of the insulin receptor's kinase domain. Prot Sci 1999; 8: 2158-65.